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Nosocomial Candida infections
The progress in medicine over the last two decades
with introduction of new technologies and therapies,
which has allowed the survival of more and more pa-
tients suffering from serious diseases, has brought
about an increase in the number of hospitalised and im-
munocompromised subjects. These individuals are
highly susceptible to nosocomial fungal infections, es-
pecially to candidosis. Candida spp. infections range
from thrush to invasive diseases such as arthritis, os-
teomyelitis, endocarditis, endophthalmitis, meningitis,
or fungaemia [1, 2].
Nosocomial candidosis may be exogenous or endoge-
nous. Although the finding of Candida on superficial
body sites cannot be considered evidence of infection,
the adhesion and persistence of yeast on these surfaces
is the first step in the development of candidosis. Dis-
seminated candidosis is commonly associated with an
inadequate immune response, sometimes with an ab-
normal production of IgA. This allows the invasion of
the mucosal barriers, in proportion to the magnitude of
colonisation [3-5].
Genotypical analyses carried out on colonising and in-
fecting strains showed that strains causing infections of-
ten originate from a commensal population on the body
surface and/or gastrointestinal tract of patients [3, 6].
This is supported by cases of candidaemia that occurred
in patients in bone marrow transplant and haematol-
ogy/oncology units, in positive-pressure or private
rooms. In these situations, isolation, the proper em-
ployment of hygienic measures by the hospital person-
nel and the provision of specialized diets minimize the
risk of cross-infection from patient to patient [2].
The exogenous acquisition of nosocomial candidosis is
proved by several reported outbreaks. These cases seem
to be associated with environmental factors, such as the
presence of multiple doors into the rooms, the trans-
portation of patients to different units or the contamina-
tion of liquid for infusion and biomaterials, but above
all with the behaviour of the personnel [2, 3, 6, 7]. Stud-
ies carried out using different methods to verify the
similarity among strains isolated from the hands of
health care workers (HCWs) and strains colonising
their patients demonstrated the role of personnel in the
spread of infection; C. parapsilosis and C. albicans are
the species most frequently isolated from the hands of
HCWs [3, 8, 9].
The differentiation between endogenous and exoge-
nous infections is important to determine suitable con-
trol measures to prevent further transmission of Can-
dida [2].
Over the last 20 years there has been world-wide in-
crease in mucocutaneous and invasive fungal infec-
tions [3]. The 115 hospitals participating in the Na-
tional Nosocomial Infections Surveillance (NNIS)
system reported between 1980 and 1990 an increase
in the rate of nosocomial fungal infections from 2.0 to
3.8 per 1,000 discharges [10]. This trend was observed
for all clinical manifestations including oropharyn-
geal infections, surgical site infections, and urinary
tract infections, but especially for fungaemia, which
rose from 5.4% of all nosocomial bloodstream infec-
tions (BSI) in 1980 to 9.9% in 1990 [2, 10]. In addi-
tion to the increase in the incidence of endemic noso-
comial fungal infections, numerous nosocomial fun-
gal outbreaks were reported [2, 4].
In the European Prevalence of Infection in Intensive
Care (EPIC) study, carried out in 1992 on 1,417 inten-
sive care units (ICUs) in 14 European countries, 17.1%
were fungal infections. Fungi were the fifth most com-
mon cause of nosocomial infections after Enterobacte-
riaceae, Staphylococcus aureus, Pseudomonas aerugi-
nosa and coagulase-negative staphylococci [4, 12].
The majority of nosocomial fungal infections are re-
ported to be caused by Candida spp. [2, 10]. C. albi-
cans is the single most common species causing infec-
tions. The NNIS reported in 1990-1992 C. albicans as
ranking seventh among the pathogens isolated from
major infection sites (i.e., urinary tract, surgical site,
bloodstream and lungs) [2, 13]. C. albicans accounted
for 76% of 24,227 cases of candidosis reported in the
NNIS hospitals in the period 1980-1990, with an in-
crease in the proportion of nosocomial infections from
2% in 1980 to 5% in 1986-89; in the Netherlands it ac-
counted for 73% of all Candida infections [3, 4, 14].
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The second species most frequently associated to human
infections is C. glabrata in the USA and Norway, and C.
parapsilosis in Canada and South America [16-18].
C. albicans, C. parapsilosis, C. tropicalis, C. glabrata
and C. krusei cause the most common clinical manifes-
tations; at times other species such as C. dubliniensis,
C. guillermondii, C. kefyr, C. lipolytica, C. lusitaniae
and C. rugosa are involved.
The presence of C. albicans on mucosal surfaces may
become the cause of chronic infections in individuals
with insufficient or absent immune cell-mediated
mechanisms. Critically ill and neutropenic patients are
particularly at risk of developing invasive C. albicans
infections, with fungaemia and the involvement of
multiple organs.
C. tropicalis is isolated less frequently than albicans in
the hospital setting, but it is an important cause of in-
vasive candidosis, especially in leukemic patients [19].
Like C. albicans, parapsilosis is a commensal of sev-
eral body sites. This species is often isolated from the
blood of hospitalised patients, with various prevalence
rates among different structures [19, 20]. Unlike albi-
cans and tropicalis, C. parapsilosis in most cases orig-
inates from an environmental source: nosocomial in-
fections caused by this species are frequently associat-
ed to the employment of a prosthesis or the application
of invasive procedures. In several reports on the out-
breaks of fungaemia, endophthalmitis and endocarditis
caused by C. parapsilosis, the fluids for parenteral nu-
trition, intravascular devices, ophthalmic solutions and
glove laceration during surgical procedures were
shown to be involved [19, 21].
C. krusei can colonise the gastrointestinal, respiratory
and urinary tracts and produce opportunistic invasive
infections in neutropenic patients, particularly those
with leukemia. A deterioration of the gastrointestinal
mucosa subsequent to cytotoxic chemo- or radiothera-
py is a risk factor for the development of C. krusei fun-
gaemia. A high mortality is associated to this species
for neutropenic patients [19, 22].
Candidaemia caused by glabrata have a higher compli-
cation rate than that caused by other non albicans
species. The management of patients infected by
glabrata or krusei is difficult due to their reduced sus-
ceptibility to azoles [19].
Nosocomial candidaemia
The invasive Candida spp. infections are candidaemia
and disseminated or systemic candidosis. Systemic
candidosis refers to the presence of yeast in non-adja-
cent, normally sterile sites, demonstrated by culture or
histological analysis. The isolation of Candida from the
blood of patients with clinical signs of infection is evi-
dence of candidaemia, even though the clinical signs
may be lacking in neutropenic patients or in subjects
receiving steroids [1].
Candidaemia is widely studied, as it accounts for 10-
20% of all candidosis and is the most common fungal
bloodstream infection [1, 2, 7, 10, 15, 23].
Although the surveillance studies to date were not co-
ordinated, the results contribute to delineating the epi-
demiology of candidaemia [24].
In the last two decades, the increasing number of im-
munocompromised patients has brought about a rise in
the incidence of nosocomial candidosis, which was
previously rare and limited to burn or severely trauma-
tised patients [3, 10].
The origin of this problem is relatively recent: in a re-
view of the aetiology of nosocomial BSI between 1935
and 1983, fungi (and Candida spp.) were reported only
since 1953 as the cause of 3.8% of all BSI in Boston City
Hospital [25, 26]. In the same hospital in 1972 Candida
spp. were 4.2% of agents causative of sepsis [27].
In a study carried out from 1975 to 1977 in two US
hospitals, Candida spp. were reported to be the third
most common cause of BSI [28].
The NNIS system reported an increase in the rate of
fungal BSI from 0.1 to 0.5 cases per 1,000 discharges
between 1980 and 1990. Although the contribution of
Candida spp. to this rise is not specified, 85.6% of all
nosocomial fungal infections were caused by these
yeasts [29].
Another analysis of NNIS data in 1986-1989 reported
Candida spp. as accounting for 8% of infections and
the fourth most common cause of sepsis, with albicans
accounting for 5% [14].
Other studies confirmed the increase in invasive Can-
dida spp. infections observed in 1980-1990: one of
these, carried out on two US hospitals and on the Na-
tional Hospital Discharge Survey (NHDS) data from
1980 to 1989, reported a rise in the rate of disseminat-
ed candidosis from 0.013 to 0.15 cases per 1,000 ad-
missions. The Authors defined the phenomenon as “an
epidemic of the 1980s” [29].
This trend however was not an isolated phenomenon,
but was part of the global rise in bacteraemia and fun-
gaemia in 1980-1990 [15, 25].
In contrast with the data referring to the 1980s, the in-
cidence rate levelled off or in some cases decreased
during the 1990s [1, 17, 30-34].
In accordance with what was reported by Schaberg in
the previous decade, the NNIS system showed Candida
spp. as the fourth most common cause in 14,000 cases
of BSI; similar results were registered in 1995-1998 in
49 US non-NNIS hospitals, and in 1995-1996 in the
Surveillance and Control of Pathogens of Epidemiolog-
ic Importance (SCOPE) program [8, 25, 35, 36]. A study
carried out in a US hospital from 1989 to 2000 on 328
episodes of candidaemia showed a decrease in the inci-
dence, with the highest values in 1993 and the lowest
levels in 1997 [25, 32].
As for Europe, recent surveys carried out in different
countries such as Finland, England, Holland, Spain,
Ireland, Hungary, Switzerland, Sweden and the Lom-
bardy region of Italy showed a lesser contribution of
candidaemia to nosocomial BSI than that reported in
the USA [30, 37-46].
Many of these studies were performed for the surveil-
lance study on candidaemia promoted by the European
Confederation of Medical Mycology (ECMM); the
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overall incidence was 0.20-0.38 cases per 1,000 admis-
sions [47].
On the whole, as outlined in Table I, the data collected
show, with few exceptions, an elevation in the incidence
in the early 1990s followed by a levelling off to lower
values. Furthermore, the predominance of candidaemia
in the USA compared to Europe is probably attributable
to differences in health practices. It should be taken in-
to account that the reduction reported in recent years
may be related to the specific geographical areas or sub-
populations examined. Indeed, this trend is not consis-
tent with that registered in neonatal ICUs, in which the
incidence of candidaemia increased implacably in the
1980s and still appears to be increasing [25, 48].
As for the role of the different species, C. albicans is
the most common cause of invasive infections in a
range which includes glabrata, krusei, guillermondii,
parapsilosis and tropicalis, with different geographical
distributions. In several trials carried out in USA from
1986 to 1989 and from 1995 to 1998, the percentage of
candidaemia caused by non albicans species rose from
37.5% to 46.8% [14, 25, 35]. This was confirmed by
studies carried out in USA from 1987 to 1992 and in
Dutch hospitals from 1987 to 1995 [39, 49]. The de-
crease reported by Garbino et al. in the period 1989-
2000 was attributed to a considerable reduction in C.
albicans BSI but with no modification in those caused
by non albicans species [25, 32].
In the last few years, other studies have shown an in-
crease for non albicans BSI, especially for those caused
by C. glabrata and parapsilosis [41, 45, 46, 50, 51]. The
contribution of the different species varies with the type
of patients and treatment. Oncologic patients with a
solid tumour are more frequently infected by glabrata,
which, instead, was rarely isolated in neonatal units. In
these wards, on the contrary, parapsilosis predominates
[25, 52, 53]. Non-albicans infections arise in general
after chemotherapy for haematological malignancies
rather than for solid tumours [25, 54].
Although in the last few years the contribution of non
albicans species in the aetiology of candidaemia has in-
creased, they have been responsible for a significant
proportion of invasive fungal infections for many
years. In the early trial on bacteraemia and fungaemia
carried out in 1975-1977, they caused 66.7% of candi-
daemias, of which 33.3.% of glabrata alone, i.e. simi-
lar to the incidence of albicans BSI [28].
The progressive increase in the involvement of non al-
bicans in invasive infections is correlated with a series
of epidemiological factors. For example, it has been
hypothesised that the increased use of fluconazole in
therapeutic and prophylactic treatments in the 1990s
favoured the emergence of glabrata and krusei, which
are relatively resistant to this drug [25].
According to some Authors, all patients with candi-
daemia should be treated regardless of its source or du-
ration, because of the frequency of hematogenous dis-
semination, its high mortality, and the difficulties in es-
Tab. I. Incidence of candidaemia: summary of reported studies.
Authors Year of Period Type of population, Incidence Proportion (%) Rank
publication country Rate/1.000 Rate/1.000 Rate/1.000 Rate/10.000
admissions discharges patient days CVC* days
McGowan Jr JE [27] 1975 1935-1972 single hospital, USA 0-> 2.5 0-> 4.2
Weinstein MP [28] 1983 1975-1977 two hospitals, USA 0.9 7.1 3
Beck-Sague C [10] 1993 1980-1990 NNIS hospitals, USA 0.1->0.5 (fungaemia)
Schaberg DR [14] 1991 1986-1989 NNIS hospitals, USA 8 4
Fisher-Hoch SP [29] 1995 1980-1989 NHDS hospitals , USA 0.013-> 0.15
Trick WE [92] 2002 1989-1999 1.116 NNIS ICUs, USA 9.6-> 3.7
Garbino J [32] 2002 1989-2000 single hospital, USA 0.02-0.05
NNIS [36] 1996 1986-1996 231 NNIS hospitals, USA 5 4
Edmond MB [35] 1999 1995-1998 49 hospitals, USA 7.6 4
Pfaller MA [8] 1998 1995-1996 50 SCOPE hospitals , USA 8 4
Lyytikainen O [37] 2002 1999-2000 four hospitals, Finland 4 8
NINSS [38] 2000 1997- 2000 NINSS hospitals, England 2 9
Voss A [39] 1996 1987-1995 five hospitals, Holland 0.32-> 0.74 3.2-5. 6
Alonso-Valle H [40] 2003 1995-1999 single hospital, Spain 0.81 5.2
McMullan R [41] 2002 1984-2000 single hospital, Ireland 2-2.5
Doczi I [30] 2002 1996-2000 single hospital, Hungary 0.2-0.4 1.4-2.6
Marchetti O [42] 2004 1991-2000 17 hospitals, Switzerland 2.9 7
Klingspor L [43] 2004 1998-1999 Sweden hospitals 0.32
Tortorano AM [44] 2002 1997-1999 35 hospitals, Italy (Lombardy) 0.38
Tortorano AM [47] 2004 1997-1999 106 ECMM hospitals, Europe 0.20-0.38
Boo TW [46] 2005 1999-2003 single hospital, Ireland 0.48 0:07
Peman J [45] 2005 1997-1999 19 hospitals, Spain 0.035
* Central Venous Catheter
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tablishing an accurate diagnosis. However, the treat-
ment of candidaemia is difficult because therapy
must be tailored for each individual, and consequent-
ly standard therapeutic recommendations cannot be
made [3, 55, 56].
Therefore, patients which are exposed to high risk for
development of Candida invasive infection should be
identified so that proper prophylactic treatment can be
applied [4]. Many of the studies in the literature have
allowed the role of several factors in the pathogenesis
of candidaemia to be determined. The main factors are
reported below.
PREVIOUS COLONISATION
The spread of Candida from the abdominal cavity to oth-
er body sites was first demonstrated in the 1980s [4, 57].
Analyses of different patient populations have
demonstrated the importance of a previous colonisa-
tion as a risk factor for candidaemia. In a study car-
ried out on oncologic patients, candidaemia occurred
in 32% of patients with multiple colonisation, in 1%
of patients with colonisation at a single site, and in
0.5% of those not colonised with Candida [4, 58]. A
subsequent study confirmed these data, with 22%,
5% and 0% respectively in the three groups of pa-
tients [59].
A prospective survey of 29 surgical patients colonised
by Candida spp. showed a positive correlation between
the entity of colonisation and the development of inva-
sive infections [60]. This was confirmed by a study car-
ried out on a group of low birth weight infants that cor-
related the density of colonisation, the presence of gas-
trointestinal symptoms and candidaemia [61].
A high concentration of Candida spp. in the stool of can-
cer patients was proven to be a risk factor for the devel-
opment of candidaemia [62]. In addition, the presence of
the yeast in specimens obtained from the peritoneal cav-
ity is predictive of invasive infections [1, 17, 63, 64].
The differentiation between Candida spp. colonisation
and an invasive infection in critically ill patients is still
difficult. Microbiological surveillance may help in
these cases, but the significance of positive cultures is
often unclear [65, 66]. Many Authors suggest that in
cases of clinical suspicion, the colonisation of more
than two body sites may be sufficient to predict candi-
dosis and begin antifungal therapy [1, 25, 57, 67].
THE USE OF ANTIBIOTICS
Since systemic candidosis is often the result of an ex-
cessive proliferation of yeast in the gastrointestinal
tract and a subsequent penetration of the mucosa,
which leads to the haematogenous dissemination, the
use of antibiotics is a major risk factor for candidaemia
because of the alteration they cause in the gastrointesti-
nal flora [1, 25].
Many studies have shown the importance of the num-
ber of antibiotics and the duration of their employ-
ment [60, 68]. In a survey on candidaemia patients,
94% of them had been treated with antibiotics, and
61% with more than four different agents [55].
Different types of wide spectrum drugs may have a dif-
ferent role on the predisposition of patients to exces-
sive Candida proliferation. Analyses carried out on the
effects of antibiotics have demonstrated that the in-
crease in the yeast population in the gastrointestinal tract
is correlated to a decrease in the number of anaerobic
bacteria isolated from the stools after treatment [25, 69].
Some evidence shows that therapy with cephalosporin,
particularly cephtriaxone, may readily favour the pro-
liferation of Candida compared to treatment with
aminoglycosides or imipenem [70].
NEUTROPENIA
Since neutrophils are essential components of the host
defence against mycetes, neutropenia has been shown to
be one of the major risk factors for invasive candidosis
and the most important in cancer patients [3, 71-73]. In-
tensive treatment of patients with neoplasia leads to
significant and prolonged neutropenia, which allows
the development of infection. Moreover, injuries to the
oropharyngeal mucosa caused by aggressive cytostatic
drugs such as cytarabine facilitate yeast colonisation
and subsequent invasion [68].
INTRAVASCULAR DEVICES
The care of critically ill patients often requires the use
of intravascular devices. In US hospitals they are re-
sponsible for about two thirds of BSI and 35-80% of
cases of candidaemia; particularly implicated is the
central venous catheter (CVC) [1, 31, 74, 75].
An indwelling CVC may be a substrate for the forma-
tion of a biofilm that is relatively resistant to immune
effector mechanisms and antifungal agents [25, 76].
In some studies parenteral nutrition has been associat-
ed with a significantly increased risk of candidaemia,
especially during epidemics [65].
Finally, additional risk factors have been identified,
such as certain surgical procedures, renal insufficien-
cy, the use of steroids, the severity of an underlying
disease and the length of stay in hospital. Many Au-
thors suggest that the more numerous these factors
are and the longer the exposure to them, the greater
the risk will be [1, 68, 77].
A different prevalence of various factors may, in part,
account for the geographical differences in the epi-
demiology of invasive Candida infections. At present,
the information on the prevalence of specific clinical
procedures is scanty and does not reveal the true impact
of the different healthcare practices [25].
Candidaemia is the only severe form of candidosis for
which the precise impact has been calculated. Globally,
the crude mortality rate is over 50%, with variations that
reflect the severity of underlying diseases [1, 78, 79]. In
the 1980s, Miller and Wenzel suggested that the devel-
opment of candidaemia predicted a fatal outcome [80].
This was confirmed by a subsequent study of 1,745
cases of BSI, in which candidaemia was associated
with the highest mortality rate [81].
Different mortality rates were associated with different
Candida species: the outcome of infections caused by
krusei or glabrata is worse than that of candidaemia
due to species susceptible to triazole compounds. In-
stead, a lower mortality rate was associated to candi-
daemia caused by parapsilosis.
Among the risk factors considered for their possible
role as predictors of a fatal outcome, an older age and
the severity of an underlying illness have been associ-
ated with a worse outcome, while among the control-
lable parameters the absence of antifungal treatment,
catheter removal and prolonged blood culture positivi-
ty have been identified as independent predictive fac-
tors of candidaemia.
The length of hospital stay of patients who survived
candidaemia was about 30 days longer than that of non-
infected subjects, with a consequent prolonging of care
and increased costs [1, 3, 68].
Therefore, candidaemia is associated with high mor-
bidity and mortality, and the significant employment of
additional resources. All the technical and behavioural
measures to prevent the occurrence and spread of can-
didosis may contribute to improving the safety of hos-
pitalised subjects and the prognosis of critically ill pa-
tients.
Candidaemia in Intensive Care Units
(ICUs)
ICU patients are exposed to a higher risk of nosocomi-
al BSI than other hospitalised individuals. Clinical pro-
cedures that interfere with the host barriers against the
entry of microorganisms or with the mechanisms of
eliminating them add to the critical condition of these
patients. These procedures include mechanical ventila-
tion, the employment of intravascular catheters, par-
enteral nutrition and multiple transfusions [25].
Twenty years ago Wenzel et al. reported that 45% of
nosocomial BSI occurred in ICU, despite the fact that
these units accounted for only 5-10% of hospital beds
[82].
More recently, a multicentre study carried out in France
revealed that the risk of developing nosocomial BSI is
12 times higher for ICU patients than for patients in
other wards [83].
Other surveys have shown an increasing trend for BSI
in ICU. This is especially associated with the use of in-
travascular catheters and with low respiratory tract or
intra-abdominal infections; the mortality rate is about
40% [19, 84, 85].
As for yeast invasive infections, Candida colonisation
affects 50-86% of critically ill patients during a pro-
longed stay in ICU and exposes them to a higher risk
for the development of deep infections [11, 60, 66, 68].
Surveys carried out in the 1980s reported Candida as
the fourth most common pathogen isolated in US in-
tensive care units [86]; in Europe, the EPIC study re-
ported mycetes as the fifth most common cause of
nosocomial infections in these wards [12].
The length of stay in an ICU has been shown to be a
significant risk factor for the development of candi-
daemia [87].
NNIS data reported Candida spp. to be the fourth most
common cause of BSI in these units in 1990-1999, a
similar frequency to that registered for the hospital as a
whole [88].
Fifty per cent of the cases of candidaemia that were
registered by SENTRY Antifungal Surveillance Pro-
gram in America in 1997 involved ICU patients [8].
Causing about 60% of cases, C. albicans is the most com-
mon species responsible for candidaemia, while other
species are emerging as important pathogens [8, 89, 90].
Several studies have shown an increase in the number
of non albicans BSI in ICU. A survey carried out in
Holland in 1991-1994 reported an increase from 15 to
56% [39]. The surveys carried out separately in North
and Latin America and in NNIS hospitals reported non
albicans species to be responsible for 46% of cases of
candidaemia [90, 92]. The data on the episodes of
candidaemia occurring in 1,116 NNIS ICUs from
1989 to 1999 showed a steady decrease in the inci-
dence, due to a reduction in the C. albicans infec-
tions, while no variations were found regarding non
albicans infections [25, 92].
C. glabrata cases increased from 0.2 to 0.5 for CVC
days, and this species replaced tropicalis as the second
most common cause of candidaemia [92]. The striking
increase in BSI caused by C. glabrata was probably
due to the US Food and Drug Administration’s ap-
proval of fluconazole in 1990.
In general, C. albicans strains isolated from blood are
susceptible in vitro to amphotericine B and flucona-
zole, which allows their employment in prevention and
therapy [91, 93, 94]. Therefore, the increasing use of
fluconazole in clinical practice warrants a careful mon-
itoring of fungal isolate susceptibility to prevent the
spread of resistant strains and of the species distribu-
tion to evaluate the presence of those intrinsically re-
sistant to azoles [93, 95, 96].
This monitoring should identify the onset of resistance
to other drugs such as echinocandines, particularly
caspofungin, which are frequently used for the treat-
ment of invasive candidosis due to their proven effica-
cy and safety [97].
Conclusions
As stated, a survey of candidaemia is fundamental both
for the prevention of resistance selection, through the
analysis of species distribution and antifungal suscepti-
bility, and for the control of infection transmission in
hospitals by identifying the contagion chain. Laborato-
ry analyses on the genotypical and phenotypical char-
acteristics of the isolates provide data that may identi-
fy any risk practices and indicate the choice of therapy
and suitable prevention measures.
In the last few years the surveillance of nosocomial
candidaemia has been intensified: in the USA programs
that integrate the NNIS activity have been set up, while
in Europe the ECMM has implemented a prospective
surveillance system that involves seven countries, in-
cluding Italy.
123
NOSOCOMIAL CANDIDA INFECTIONS: EPIDEMIOLOGY OF CANDIDAEMIA
References
[1] Eggimann P, Garbino J, Pittet D. Epidemiology of Candida
species infections in critically ill non-immunosuppressed pa-
tients. Lancet Infect Dis 2003;3:685-702.
[2] Fridkin SK, Jarvis WR. Epidemiology of Nosocomial Fungal
Infections. Clin Microbiol Rev 1996;9:499-511.
[3] Verduyn Lunel FM, Meis JFGM, Voss A. Nosocomial Fungal
Infections: Candidaemia. Diagn Microbiol Infect Dis
1999;34:213-20.
[4] Vincent JL, Anaissie E, Bruining H, Demajo W, el-Ebiary M,
Haber J, et al. Epidemiology, diagnosis and treatment of sys-
temic Candida infection in surgical patients under intensive
care. Intensive Care Med 1998;24:206-16.
[5] Spaeth G, Gottwald T, Specian RD, Mainous MR, Berg RD,
Deitch EA. Secretory immunoglobulin A, intestinal mucin, and
mucosal permeability in nutritionally induced bacterial
translocation in rats. Ann Surg 1994;220:798-808.
[6] Voss A, le Noble JL, Verduyn Lunel FM, Foudraine NA, Meis
JF. Candidaemia in intensive care unit patients: risk factors for
mortality. Infection 1997;25:8-11.
[7] Pfaller MA. Nosocomial candidiasis: emerging species, reser-
voirs, and modes of transmission. Clin Infect Dis 1996;22:S89-
94.
[8] Pfaller MA, Jones RN, Doern GV, Sader HS, Messer SA, Hous-
ton A, et al. National epidemiology of mycoses survey: a multi-
center study of strain variation and antifungal susceptibility
among isolates of Candida species. Diagn Microbiol Infect Dis
1998;31:289-96.
[9] Strausbaugh LJ, Sewell DL, Ward TT, Pfaller MA, Heitzman T,
Tjoelker R. High frequency of yeast carriage on hands of hos-
pital personnel. J Clin Microbiol 1994;32:2299-300.
[10] Beck-Sague C, Jarvis WR. Secular trends in the epidemiology
of nosocomial fungal infections in the United States, 1980-
1990. National Nosocomial Infections Surveillance System. J
Infect Dis 1993;167:1247-51.
[11] Vincent JL, Anaissie E, Bruining H, Demajo W, el-Ebiary M,
Haber J, et al. Epidemiology, diagnosis and treatment of sys-
temic Candida infection in surgical patients under intensive
care. Intensive Care Med 1998;24:1120-1.
[12] Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nico-
las-Chanoin MH, et al. The prevalence of nosocomial infection
in intensive care units in Europe. Results of the European
Prevalence of Infection in Intensive Care (EPIC) Study. EPIC
International Advisory Committee. JAMA 1995;274:639-44.
[13] Emori TG, Gaynes RP. An overview of nosocomial infections,
including the role of the microbiology laboratory. Clin Micro-
biol Rev 1993;6:428-42.
[14] Schaberg DR, Culver DH, Gaynes RP. Major trends in the mi-
crobial etiology of nosocomial infection. Am J Med
1991;91:72S-75S.
[15] Banerjee SN, Emori TG, Culver DH. Secular trends in nosoco-
mial primary bloodstream infections in the United States, 1980-
1989. National Nosocomial Infections Surveillance System. Am
J Med 1991;91:86S-89S.
[16] Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP.
National surveillance of nosocomial blood stream infection due
to species of Candida other than Candida albicans: frequency
of occurrence and antifungal susceptibility in the SCOPE Pro-
gram. SCOPE Participant Group. Surveillance and Control of
Pathogens of Epidemiologic. Diagn Microbiol Infect Dis
1998;30:121-9.
[17] Sandven P, Bevanger L, Digranes A, Gaustad P, Haukland HH,
Steinbakk M. Constant low rate of fungemia in Norway, 1991
to 1996. The Norwegian Yeast Study Group. J Clin Microbiol
1998;36:3455-9.
[18] Pfaller MA, Jones RN, Doern GV, Sader HS, Hollis RJ, Mess-
er SA. International surveillance of bloodstream infections due
to Candida species: frequency of occurrence and antifungal
susceptibilities of isolates collected in 1997 in the United
States, Canada, and South America for the SENTRY Program.
The SENTRY Participant Group. J Clin Microbiol
1998;36:1886-9.
[19] Mayhall CG. Hospital Epidemiology and Infection Control.
Philadelphia: Lippincott Williams & Wilkins 2004.
[20] Weems JJ Jr. Candida parapsilosis: epidemiology, pathogenic-
ity, clinical manifestations, and antimicrobial susceptibility.
Clin Infect Dis 1992;14:756-66.
[21] Lupetti A, Tavanti A, Davini P, Ghelardi E, Corsini V, Merusi I,
et al. Horizontal Transmission of Candida parapsilosis Candi-
daemia in a Neonatal Intensive Care Unit. J Clin Microbiol
2002;40:2363-9.
[22] Goldman M, Pottage JC, Weaver DC. Candida krusei
fungemia. Report of 4 cases and review of the literature. Med-
icine 1993;72:143-50.
[23] Jarvis WR. Epidemiology of nosocomial fungal infections, with
emphasis on Candida species. Clin Infect Dis 1995;20:1526-30.
[24] Pfaller MA, Diekema DJ. Role of sentinel surveillance of can-
didaemia: trends in species distribution and antifungal suscep-
tibility. J Clin Microbiol 2002;40:3551-7.
[25] Hobson RP. The global epidemiology of invasive Candida in-
fections – is the tide turning? J Hosp Infect 2003;55:159-68.
[26] McGowan JE Jr. Changing etiology of nosocomial bacteremia
and fungemia and other hospital-acquired infections. Rev In-
fect Dis 1985;7:S357-70.
[27] McGowan JE Jr, Barnes MW, Finland M. Bacteremia at Boston
City Hospital: occurrence and mortality during 12 selected
years (1935-1972), with special reference to hospital-acquired
cases. J Infect Dis 1975;132:316-35.
[28] Weinstein MP, Reller LB, Murphy JR, Lichtenstein KA. The
clinical significance of positive blood cultures: a comprehen-
sive analysis of 500 episodes of bacteremia and fungemia in
adults. I. Laboratory and epidemiologic observations. Rev In-
fect Dis 1983;5:35-53.
[29] Fisher-Hoch SP, Hutwagner L. Opportunistic candidiasis; an
epidemic of the 1980s. Clin Infect Dis 1995;21:897-904.
[30] Doczi I, Dosa E, Hajdu E, Nagy E. Aetiology and antifungal
susceptibility of yeast bloodstream infections in a Hungarian
university hospital between 1996 and 2000. J Med Microbiol
2002;51:677-81.
[31] Luzzati R, Amalfitano G, Lazzarini L, Soldani F, Bellino S,
Solbiati M, et al. Nosocomial candidaemia in non-neutropenic
patients at an Italian tertiary care center. Eur J Clin Microbiol
Infect Dis 2000;19:602-7.
However, as reported, the data available on the epi-
demiology of candidaemia are often discordant. This is
certainly due to a different geographical distribution of
the species, but also to a different influence of the risk
factors associated to the clinical practices, to the local
situations, and to the differences in the study design
and data collection.
Therefore, an intensification and improvement in the
surveillance programs, through the standardisation of
protocols, is warranted to define more exhaustively the
epidemiology of candidaemia.
F. GALLÈ ET AL.*
124
125
NOSOCOMIAL CANDIDA INFECTIONS: EPIDEMIOLOGY OF CANDIDAEMIA
[32] Garbino J, Kolarova L, Rohner P, Lew D, Pincha P, Pittet D.
Secular trends of candidaemia over 12 years in adult patients
at a tertiary care hospital. Medicine 2002;81:425-33.
[33] Krcmery VJ, Kovacicova G. Longitudinal 10-year prospective
survey of fungaemia in Slovak Republic: trends in etiology in
310 episodes. Diagn Microbiol Infect Dis 2000;36:7-11.
[34] Malani PN, Bradley SF, Little RS, Kauffman CA. Trends in
species causing fungaemia in a tertiary care medical centre
over 12 years. Mycoses 2001;44:446-9.
[35] Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN,
Wenzel RP. Nosocomial bloodstream infections in United
States hospitals: a three-year analysis. Clin Infect Dis
1999;29:239-44.
[36] Hospital Infections Program, National Center for Infectious
Diseases, Center for Disease Control and Prevention. National
Nosocomial Infections Surveillance (NNIS) report, data sum-
mary from October 1986-April 1996, issued May 1996. Am J
Infect Control 1996;24:380-8.
[37] Lyytikainen O, Lumio J, Sarkkinen H, Kolho E, Kostiala A,
Ruutu P. Hospital Infection Surveillance Team. Nosocomial
bloodstream infections in Finnish hospitals during 1999-2000.
Clin Infect Dis 2002;35:14-9.
[38] Nosocomial Infection National Surveillance System. NINSS re-
ports on surgical site infection and hospital acquired bacter-
aemia. Commun Dis Rep CDR Wkly 2000;10:213-6.
[39] Voss A, Kluytmans JA, Koeleman JG, Spanjaard L, Vanden-
broucke-Grauls CM, Verbrugh HA, et al. Occurrence of yeast
bloodstream infections between 1987 and 1995 in five Dutch
university hospitals. Eur J Clin Microbiol Infect Dis
1996;15:909-12.
[40] Alonso-Valle H, Acha O, Garcia-Palomo JD, Farinas-Alvarez
C, Fernandez-Mazarrasa C, Farinas MC. Candidaemia in a ter-
tiary care hospital: epidemiology and factors influencing mor-
tality. Eur J Clin Microbiol Infect Dis 2003;22:254-7.
[41] McMullan R, McClurg R, Xu J, Moore JE, Millar BC, Crowe
M, et al. Trends in the epidemiology of Candida bloodstream
infections in Northern Ireland between January 1984 and De-
cember 2000. J Infect 2002;45:25-8.
[42] Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C,
Garbino J, et al. Epidemiology of candidaemia in Swiss tertiary
care hospitals: secular trends, 1991-2000. Clin Infect Dis
2004;38:311-20.
[43] Klingspor L, Tornqvist E, Johansson A, Petrini B, Forsum U,
Hedin G. A prospective epidemiological survey of candidaemia
in Sweden. Scand J Infect Dis 2004;36:52-5.
[44] Tortorano AM, Biraghi E, Astolfi A, Ossi C, Tejada M, Farina
C, et al. European Confederation of Medical Mycology
(ECMM) prospective survey of candidaemia: report from one
Italian region. J Hosp Infect 2002;51:297-304.
[45] Peman J, Canton E, Gobernado M; Spanish ECMM Working
Group on Candidaemia. Epidemiology and antifungal suscepti-
bility of Candida species isolated from blood: results of a 2-
year multicentre study in Spain. Eur J Clin Microbiol Infect Dis
2005;24:23-30.
[46] Boo TW, O’Reilly B, O’Leary J, Cryan B. Candidaemia in an
Irish tertiary referral hospital: epidemiology and prognostic
factors. Mycoses 2005;48:251-9.
[47] Tortorano AM, Peman J, Bernhardt H, Klingspor L, Kibbler
CC, Faure O, et al. Epidemiology of candidaemia in Europe: re-
sults of 28-month European Confederation of Medical Mycolo-
gy (ECMM) hospital-based surveillance study. Eur J Clin Mi-
crobiol Infect Dis 2004;23:317-22.
[48] Kossoff EH, Buescher ES, Karlowicz MG. Candidaemia in a
neonatal intensive care unit: trends during fifteen years and
clinical features of 111 cases. Pediatr Infect Dis J 1998;17:504-
8.
[49] Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibili-
ties of Candida species and distribution of species recovered
from blood cultures over a 5-year period. Antimicrob Agents
Chemother 1994;38:1422-7.
[50] Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Varti-
varian S. The epidemiology of hematogenous candidiasis caused
by different Candida species. Clin Infect Dis 1997;24:1122-8.
[51] Cliff PR, Sandoe JA, Heritage J, Barton RC. Retrospective sur-
vey of candidaemia in hospitalized patients and molecular in-
vestigation of a suspected outbreak. J Med Microbiol
2005;54:391-4.
[52] Krcmery V, Barnes AJ. Non-albicans Candida spp. causing
fungaemia: pathogenicity and antifungal resistance. J Hosp In-
fect 2002;50:243-60.
[53] Rangel-Frausto MS, Wiblin T, Blumberg HM, Saiman L, Pat-
terson J, Rinaldi M, et al. National epidemiology of mycoses
survey (NEMIS): variations in rates of bloodstream infections
due to Candida species in seven surgical intensive care units.
Clin Infect Dis 1999;29:253-8.
[54] Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Van-
dercam B, et al. Candidaemia in cancer patients: a prospective,
multicenter surveillance study by the Invasive Fungal Infection
Group (IFIG) of the European Organization for Research and
Treatment of Cancer (EORTC). Clin Infect Dis 1999;28:1071-9.
[55] Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan
WC. Candidaemia in a tertiary care hospital: epidemiology,
risk factors, and predictors of mortality. Clin Infect Dis
1992;15:414-21.
[56] Solomkin JS. Pathogenesis and management of Candida infec-
tion syndromes in non-neutropenic patients. New Horiz
1993;1:202-13.
[57] Solomkin JS, Flohr AB, Quie PG, Simmons RL. The role of
Candida in intraperitoneal infections. Surgery 1980;88:524-30.
[58] Martino P, Girmenia C, Venditti M, Micozzi A, Santilli S, Bur-
gio VL, et al. Candida colonisation and systemic infection in
neutropenic patients. A retrospective study. Cancer
1989;64:2030-4.
[59] Martino P, Girmenia C, Micozzi A, Raccah R, Gentile G, Ven-
ditti M, et al. Fungemia in patients with leukemia. Am J Med
Sci 1993;306:225-32.
[60] Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Can-
dida colonisation and subsequent infections in critically ill sur-
gical patients. Ann Surg 1994;220:751-8.
[61] Pappu-Katikaneni LD, Rao KP, Banister E. Gastrointestinal
colonisation with yeast species and Candida septicemia in very
low birth weight infants. Mycoses 1990;33:20-3.
[62] Richet HM, Andremont A, Tancrede C, Pico JL, Jarvis WR.
Risk factors for candidaemia in patients with acute lymphocyt-
ic leukemia. Rev Infect Dis 1991;13:211-5.
[63] Calandra T, Bille J, Schneider R, Mosimann F, Francioli P.
Clinical significance of Candida isolated from peritoneum in
surgical patients. Lancet 1989;2:1437-40.
[64] Sandven P, Qvist H, Skovlund E, Giercksky KE. Significance of
Candida recovered from intraoperative specimens in patients
with intra-abdominal perforations. Crit Care Med
2002;30:541-7.
[65] Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson
JE, Pfaller MA et al. Risk factors for candidal bloodstream in-
fections in surgical intensive care unit patients: the NEMIS
prospective multicenter study. Clin Infect Dis 2001;33:177-86.
[66] Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Effects of
nosocomial candidaemia on outcomes of critically ill patients.
Am J Med 2002;113:480-5.
[67] Edwards JE Jr, Bodey GP, Bowden RA, Buchner T, de Pauw
BE, Filler SG et al. International conference for the develop-
ment of a consensus on the management and prevention of se-
vere candidal infections. Clin Infect Dis 1997;25:43-59.
[68] Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk
factors for hospital-acquired candidaemia. A matched case-
control study. Arch Intern Med 1989;149:2349-53.
[69] Giuliano M, Barza M, Jacobus NV, Gorbach SL. Effect of
broad-spectrum parenteral antibiotics on composition of in-
testinal microflora of humans. Antimicrob Agents Chemother
1987;31:202-6.
[70] Samonis G, Anaissie EJ, Bodey GP. Effects of broad-spectrum
antimicrobial agents on yeast colonisation of the gastrointesti-
nal tracts of mice. Antimicrob Agents Chemother
1990;34:2420-2.
[71] Nucci M, Colombo AL. Risk factors for breakthrough candi-
daemia. Eur J Clin Microbiol Infect Dis 2002;21:209-11.
[72] Bow EJ, Loewen R, Cheang MS, Schacter B. Invasive fungal
disease in adults undergoing remission-induction therapy for
acute myeloid leukemia: the pathogenetic role of the an-
tileukemic regimen. Clin Infect Dis 1995;21:361-9.
[73] Guiot HF, Fibbe WE, van’t Wout JW. Risk factors for fungal in-
fection in patients with malignant hematologic disorders: im-
plications for empirical therapy and prophylaxis. Clin Infect
Dis 1994;18:525-32.
[74] Safdar N, Maki DG. The commonality of risk factors for noso-
comial colonisation and infection with antimicrobial-resistant
Staphylococcus aureus, enterococcus, gram-negative bacilli,
Clostridium difficile, and Candida. Ann Intern Med
2002;136:834-44.
[75] Pittet D, Wenzel RP. Nosocomial bloodstream infections. Secu-
lar trends in rates, mortality, and contribution to total hospital
deaths. Arch Intern Med 1995;155:1177-84.
[76] Douglas LJ. Candida biofilms and their role in infection.
Trends Microbiol 2003;11:30-6.
[77] Wenzel RP. Nosocomial candidaemia: risk factors and attrib-
utable mortality. Clin Infect Dis 1995;20:1531-4.
[78] Gudlaugsson O, Gillespie S, Lee K. Attributable mortality of
nosocomial candidaemia, revisited. Clin Infect Dis
2003;37:1172-7.
[79] Charles PE, Doise JM, Quenot JP, Aube H, Dalle F, Chavanet
P, et al. Candidaemia in critically ill patients: difference of out-
come between medical and surgical patients. Intensive Care
Med 2003;29:2162-9.
[80] Miller PJ, Wenzel RP. Etiologic organisms as independent pre-
dictors of death and morbidity associated with bloodstream in-
fections. J Infect Dis 1987;156:471-7.
[81] Pittet D, Li N, Woolson RF, Wenzel RP. Microbiological fac-
tors influencing the outcome of nosocomial bloodstream infec-
tions. A six year validated, population-based model. Clin Infect
Dis 1997;24:1068-78.
[82] Wenzel RP, Thompson RL, Landry SM. Hospital-acquired in-
fection in intensive care unit patients: an overview with em-
phasis on epidemics. Infect Control 1983;4:371.
[83] Brun-Buisson C, Doyon F, Carlet J. Bacteremia and severe sep-
sis in adults: a multicenter prospective survey in ICUs and
wards of 24 hospitals. Am J Respir Crit Care Med
1996;154:617-24.
[84] Valles J, Leon C, Alvarez-Lerma F. Nosocomial bacteremia in
critically ill patients: a multicenter study evaluating epidemiol-
ogy and prognosis. Clin Infect Dis 1997;24:387-95.
[85] Edgeworth JD, Treacher DF, Eykyn SJ. A 25-year study of
nosocomial bacteremia in an adult intensive care unit. Crit
Care Med 1999;27:1421-8.
[86] Jarvis WR, Martone WJ. Predominant pathogens in hospital in-
fections. J Antimicrob Chemother 1992;29:19-24.
[87] Puzniak L, Teutsch S, Powderly W, Polish L. Has the epidemi-
ology of nosocomial candidaemia changed? Infect Control
Hosp Epidemiol 2004;25:628-33.
[88] Hospital Infections Program, National Center for Infectious
Diseases, Center for Disease Control and Prevention. National
Nosocomial Infections Surveillance (NNIS) report, data sum-
mary from January 1990-May 1999, issued June 1999. Am J In-
fect Control 1999;27:520-32.
[89] Peres-Bota D, Rodriguez-Villalobos H, Dimopoulos G, Melot
C, Vincent JL. Potential risk factors for infection with Candida
spp. in critically ill patients. Clin Microbiol Infect
2004;10:550-5.
[90] Nguyen MH, Peacock JE Jr, Morris AJ, Tanner DC, Nguyen
ML, Snydman DR, et al. The changing face of candidaemia:
emergence of non-Candida albicans species and antifungal re-
sistance. Am J Med 1996;100:617-23.
[91] Pfaller MA, Jones RN, Doern GV. Bloodstream infections due
to Candida species: SENTRY antimicrobial surveillance pro-
gram in North America and Latin America, 1997-1998. An-
timicrob Agents Chemother 2000;44:747-51.
[92] Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP.
National Nosocomial Infections Surveillance System Hospitals.
Secular trend of hospital-acquired candidaemia among inten-
sive care unit patients in the United States during 1989-1999.
Clin Infect Dis 2002;35:627-30.
[93] Diekema DJ, Messer SA, Brueggemann AB, Coffman SL, Do-
ern GV, Herwaldt LA, et al. Epidemiology of candidaemia: 3-
year results from the emerging infections and the epidemiology
of Iowa organisms study. J Clin Microbiol 2002;40:1298-302.
[94] Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hol-
lis RJ, et al. International surveillance of bloodstream infec-
tions due to Candida species: frequency of occurrence and in
vitro susceptibility to fluconazole, ravuconazole, and voricona-
zole of isolates collected from 1997 through 1999 in the SEN-
TRY Antimicrobial Surveillance Program. J Clin Microbiol
2001;39:3254-9.
[95] Berrouane YF, Herwaldt LA, Pfaller MA. Trends in antifungal
use and epidemiology of nosocomial yeast infections in a uni-
versity hospital. J Clin Microbiol 1999;37:531-7.
[96] Collin B, Clancy CJ, Nguyen MH. Antifungal resistance in
non-albicans Candida species. Drug Resist 1999;3:9-14.
[97] Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-
Moya L, Smietana J, et al. Comparison of caspofungin and am-
photericin B for invasive candidiasis. N Engl J Med
2002;347:2020-9.
F. GALLÈ ET AL.*
126
n Received on October 27, 2005. Accepted on January 30, 2006.
n Correspondence: Prof. Giorgio Liguori, Chair of Hygiene and
Epidemiology, Department of Studies of Institutions and Territo-
rial Systems, University “Parthenope” of Naples, via Medina 40,
80133 Naples, Italy - Tel./Fax +39 081 5474790 - E-mail: gior-
gio.liguori@uniparthenope.it
                                                                 
